Scott McMillan is joining uniQure (NASDAQ: QURE) as chief operating officer. Before coming to uniQure, a gene therapy developer split between The Netherlands and Lexington, MA, McMillan was senior vice president of quality and technical operations at AMAG Pharmaceuticals (NASDAQ: AMAG) in Waltham, MA. McMillan will be based at uniQure’s Lexington site.
In other moves, uniQure appointed Sander van Deventer as chief scientific officer, succeeding Harald Petry, who is retiring. Van Deventer is a company co-founder and has been a board member since 2010. Shareholders are expected to appoint his replacement on the board on Sept. 14. UniQure also promoted Christian Klemt from global controller to chief accounting officer. UniQure is currently in clinical trials testing an experimental gene therapy for hemophilia B.